179 related articles for article (PubMed ID: 38307859)
21. Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8
Zhang X; Wei Z; Yong T; Li S; Bie N; Li J; Li X; Liu H; Xu H; Yan Y; Zhang B; Chen X; Yang X; Gan L
Nat Commun; 2023 Sep; 14(1):5653. PubMed ID: 37704614
[TBL] [Abstract][Full Text] [Related]
22. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Scherrer D; Barrett N; Teyton L; Pearce T; Nitcheu J; Pouletty P; Santo J; Ehrlich HJ
Mol Cancer Ther; 2022 Dec; 21(12):1788-1797. PubMed ID: 36198025
[TBL] [Abstract][Full Text] [Related]
23. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
Wang X; Zhou T; Chen X; Wang Y; Ding Y; Tu H; Gao S; Wang H; Tang X; Yang Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246476
[TBL] [Abstract][Full Text] [Related]
24. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
Tan Z; Chiu MS; Yang X; Yue M; Cheung TT; Zhou D; Wang Y; Chan AW; Yan CW; Kwan KY; Wong YC; Li X; Zhou J; To KF; Zhu J; Lo CM; Cheng AS; Chan SL; Liu L; Song YQ; Man K; Chen Z
Gut; 2023 Aug; 72(8):1568-1580. PubMed ID: 36450387
[TBL] [Abstract][Full Text] [Related]
25. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
26. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
27. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
28. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
29. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
[TBL] [Abstract][Full Text] [Related]
30. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
31. Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma.
Song Z; Wang X; Liu X; Luo Y; Qiu J; Yin A; Liu Y; Yi H; Xiao Z; Li A
Biochem Pharmacol; 2023 Jul; 213():115612. PubMed ID: 37209858
[TBL] [Abstract][Full Text] [Related]
32. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
[TBL] [Abstract][Full Text] [Related]
33. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
34. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
35. Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.
Hu Z; Chen G; Zhao Y; Gao H; Li L; Yin Y; Jiang J; Wang L; Mang Y; Gao Y; Zhang S; Ran J; Li L
Mol Cancer; 2023 Mar; 22(1):55. PubMed ID: 36932387
[TBL] [Abstract][Full Text] [Related]
36. Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma.
Mi H; Ho WJ; Yarchoan M; Popel AS
Front Immunol; 2022; 13():892250. PubMed ID: 35634309
[TBL] [Abstract][Full Text] [Related]
37. GOLM1 exacerbates CD8
Chen J; Lin Z; Liu L; Zhang R; Geng Y; Fan M; Zhu W; Lu M; Lu L; Jia H; Zhang J; Qin LX
Signal Transduct Target Ther; 2021 Nov; 6(1):397. PubMed ID: 34795203
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
Sasaki T; Shigeta K; Kitahara S; Suzuki Y; Matsui S; Seishima R; Okabayashi K; Duda DG; Kitagawa Y
Anticancer Res; 2022 Nov; 42(11):5205-5215. PubMed ID: 36288859
[TBL] [Abstract][Full Text] [Related]
39. Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling.
Wen J; Yang S; Yan G; Lei J; Liu X; Zhang N; Zhang J; Deng H; Wu L; Li Y
Exp Cell Res; 2023 Jul; 428(2):113651. PubMed ID: 37201744
[TBL] [Abstract][Full Text] [Related]
40. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
Yao W; Ba Q; Li X; Li H; Zhang S; Yuan Y; Wang F; Duan X; Li J; Zhang W; Wang H
EBioMedicine; 2017 Aug; 22():58-67. PubMed ID: 28754304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
